Literature DB >> 8348757

Surface expression of adenosine deaminase in mitogen-stimulated lymphocytes.

M Martin1, J J Centelles, J Huguet, F Echevarne, D Colomer, J L Vives-Corrons, R Franco.   

Abstract

Adenosine deaminase (ADA) expression on the surface of mitogen-stimulated lymphocytes was studied by flow cytometry. The gate for lymphocytes was located by cell size (forward scatter), cytoplasmic complexity (side scatter) and by expression of the markers CD2, CD4, CD8 and CD19. After mitogenic proliferation two populations appeared, one corresponding to non-stimulated cells, and the other consisting of larger cells which showed relatively high expression of adenosine deaminase on their surface. The increase was similar to that observed for CD71 expression, and paralleled the increase in 3H-thymidine incorporation. There was a correlation between ADA and CD71 expression (r = 0.92 for phytohaemagglutinin (PHA) and 0.97 for pokeweed mitogen (PWM)). These results suggest a role for ecto-adenosine deaminase in lymphocyte proliferation and/or triggering.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348757      PMCID: PMC1554837          DOI: 10.1111/j.1365-2249.1993.tb07981.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Adenosine deaminase activity in lymphoid cells during antibody production.

Authors:  J G HALL
Journal:  Aust J Exp Biol Med Sci       Date:  1963-02

2.  Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs.

Authors:  J J Barchi; V E Marquez; J S Driscoll; H Ford; H Mitsuya; T Shirasaka; S Aoki; J A Kelley
Journal:  J Med Chem       Date:  1991-05       Impact factor: 7.446

3.  Purine degradative enzymes in circulating malignant cells of patients with chronic B cell neoplasia.

Authors:  A D Ho; W Knauf; K Ganeshaguru; W Hunstein; A V Hoffbrand
Journal:  Hematol Oncol       Date:  1987 Jan-Mar       Impact factor: 5.271

4.  Ecto-5'-nucleotidase expression during human B cell development. An explanation for the heterogeneity in B lymphocyte ecto-5'-nucleotidase activity in patients with hypogammaglobulinemia.

Authors:  L F Thompson; J M Ruedi; R D O'Connor; J F Bastian
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

5.  Serum and pleural adenosine deaminase. Correlation with lymphocytic populations.

Authors:  M F Baganha; A Pêgo; M A Lima; E V Gaspar; A R Cordeiro
Journal:  Chest       Date:  1990-03       Impact factor: 9.410

6.  Production of antisera with small doses of immunogen: multiple intradermal injections.

Authors:  J L Vaitukaitis
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

7.  Decreased adenosine deaminase (ADA) and 5'nucleotidase (5NT) activity in peripheral blood T cells in Hodgkin disease.

Authors:  J L Murray; R Perez-Soler; D Bywaters; E M Hersh
Journal:  Am J Hematol       Date:  1986-01       Impact factor: 10.047

8.  Adenosine deaminase of cultured brain cells.

Authors:  E G Trams; C J Lauter
Journal:  Biochem J       Date:  1975-12       Impact factor: 3.857

9.  Studies on terminal deoxynucleotidyl transferase and adenosine deaminase in myasthenic thymus.

Authors:  P Vezzoni; F Fiacchino; L Clerici; A Sghirlanzoni; D Cerrato; D Peluchetti; R Lucchini; M Raineri; F Cornelio
Journal:  J Neuroimmunol       Date:  1984 Sep-Oct       Impact factor: 3.478

10.  Elevated adenosine deaminase and purine nucleoside phosphorylase activity in peripheral blood null lymphocytes from patients with acquired immune deficiency syndrome.

Authors:  J L Murray; K C Loftin; C G Munn; J M Reuben; P W Mansell; E M Hersh
Journal:  Blood       Date:  1985-06       Impact factor: 22.113

View more
  2 in total

1.  Role of microglial cells in selective replication of simian immunodeficiency virus genotypes in the brain.

Authors:  Tahar Babas; Daniel Muñoz; Joseph L Mankowski; Patrick M Tarwater; Janice E Clements; M Christine Zink
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 2.  Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy.

Authors:  Rafael Franco; Rafael Rivas-Santisteban; Gemma Navarro; Irene Reyes-Resina
Journal:  Cells       Date:  2021-10-21       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.